Disease X

Disease X

Kate Kelland

28,58 €
IVA incluido
Disponible
Editorial:
Canbury Press Ltd
Año de edición:
2024
Materia
Enfermedades infectocontagiosas
ISBN:
9781912454976
28,58 €
IVA incluido
Disponible
Añadir a favoritos

'DISEASE X sets out a game-changing plan for how the world can learn from Covid-19 and be ready for the next pandemic.' - Tony Blair, former British Prime MinisterDISEASE X is a fast-paced, almost real-time account of how international scientists and global public health leaders are preparing the world to be able to contain outbreaks of new and re-emerging infectious diseases before they become global contagions.Disease X is the codename given by the World Health Organisation to a pathogen currently unknown to science with the potential to cause havoc to humankind. Emerging infections - such as the recent outbreaks of new variants of H5N1 bird flu and mpox - are sending us multiple warnings that another Disease X is looming.New pathogens are occurring at an increasing cadence: we had SARS in 2002, H5N1 bird flu in 2004, H1N1 ’swine flu’ in 2009, MERS in 2012, Ebola in 2014, Zika in 2015, Covid-19 in 2019, and now mpox in Africa and a new H5N1 avian flu that has infected livestock.Written by a long-standing ex-Reuters global health and science correspondent, DISEASE X uses privileged access to the body leading international efforts to control viral outbreaks, the Coalition for Epidemic Preparedness Innovations (CEPI), and its CEO, Dr Richard Hatchett. CEPI seed-funded three successful COVID vaccines, including the AstraZeneca and Moderna shots.Weaving in insights from the likes of Bill Gates, Erna Solberg, Jeremy Farrar and Seth Berkley, the book explores the emergence of the novel coronavirus and the deadly crisis it caused. It analyses the responses of global health organisations and experts, including the WHO; national governments in Britain, China and the USA; COVAX, the global vaccine allocation facility; pharmaceutical companies; and leading research scientists.Ultimately, DISEASE X tells how, throughout the devastation of Covid, science and human ingenuity have shown that the world can devise intricate new weapons at a breathtaking pace against new deadly diseases.It tells how the world’s public health scientists are embarking on a 100 Days Mission to embed that scientific progress into a pandemic-busting plan to defuse future threats from as-yet-unknown pathogens in a little over three months. This is the 100 Days Mission - backed by the G7 and G20 - that will see a newly prepared world move at speed to snuff out future threats before they become deadly pandemics.Foreword by the former UK PM Tony Blair.Reviews'An engaging, accessible and ultimately optimistic account of how nations, institutions and the scientific community responded to Covid and how they could work together in future.' - Fergus Walsh, BBC Medical Editor 'As Kelland argues cogently, fear of the next outbreak should not paralyse us but instead galvanise us into making sure the terrible toll of Covid-19 is not repeated. DISEASE X is a valuable policy roadmap in a world custom-built for pandemics.' - Anjana Ahuja, co-author of Spike: The Virus Vs The People'With access to key players on the frontlines, DISEASE X takes us inside the effort to prevent future outbreaks from exploding into global disasters... this important book outlines why it will be vital to keep pandemic threats at the top of our priority list for decades to come.' - James Paton, former Health Correspondent for Bloomberg News

Artículos relacionados

  • Molecular Virology and Control of Flaviviruses
    Pei-Yong Shi
    Flaviviruses are a diverse group of small RNA enveloped viruses, many of which are important human and animal pathogens. The best known include dengue virus, yellow fever virus, Japanese encephalitis virus, and West Nile virus. These viruses are endemic in many tropical and sub-tropical regions of the world. Dengue virus alone infects over 100 million people annually. In recent...
  • Leishmania
    Every year, with an estimated 1.3 million new cases and more than 20,000 deaths, Leishmaniasis continues to be a menace in countries across the globe. With the absence of an anti-Leishmania vaccine - along with the toxicity of current anti-parasite drugs and coupled with the rapid emergence of drug resistant Leishmania strains - there remains significant challenges for disease ...
  • Oral Microbiome in Endocarditis Patients
    Sathya Narayanan.G
    The book 'Oral Microbiome in Endocarditis Patients' focuses on the analysis of the human oral microbiome in patients with infective endocarditis and healthy individuals. The author, Sathya Narayanan.G, uses 16S rRNA metagenomic analysis to investigate the microbial diversity and composition of the oral cavity in these two groups. The book highlights the importance of oral healt...
  • ENFERMEDADES NOSOCOMIALES. MICROORGANISMOS CAUSALES
    JOSE ALBERTO ALARCÓN MARTÍNEZ
    El libro define una infección nosocomial, cómo se transmiten, tipos de infecciones que las causan, cómo prevenirlas y los principales agentes causales que las producen, ya sean bacterias, virus u hongos. ...
    Disponible

    16,44 €

  • The Demodex Solution
    Dr. Anna Ivakhnenko
    Wondering if your skin concerns like acne, rosacea, red nose, pimples, and a range of other conditions could be linked to Demodex mites? Discover the ultimate solution in this comprehensive guide to regain your skin’s health.Enter the microscopic world of Demodex mites and explore their potential connection to a myriad of skin conditions such as rosacea, blepharitis, seborrheic...
    Disponible

    39,81 €

  • Bacterial Infectious Diseases Annual Volume 2023
    Despite the development of numerous antimicrobial agents, the successful eradication of bacterial infections remains a challenge, and bacteria continue to pose a major public health threat. It is estimated that, due to the increasing prevalence of antibiotic resistance, infectious diseases will become a leading cause of death by 2050. The current annual focus is on the challeng...
    Disponible

    155,59 €